** Shares of Applied Therapeutics APLT.O fall 80.3% to $1.70 after the bell
** Company says the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic metabolic disease
** The FDA's letter to the company said the marketing application for the drug, govorestat, cannot be approved in its current form, due to certain deficiencies - APLT
** Galactosemia can cause neurological complications, including deficiencies in speech, cognition, behavior and motor skills
** Up to last close, stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。